144 related articles for article (PubMed ID: 33766464)
1. Systemic dissemination of tumor cells during transurethral resection in patients with bladder tumor and its clinical relevance: A follow up study.
Nayyar R; Saini S; Sharma A; Kurra S; Dogra PN
Urol Oncol; 2021 Aug; 39(8):497.e17-497.e22. PubMed ID: 33766464
[TBL] [Abstract][Full Text] [Related]
2. Expressions of P-Glycoprotein, Multidrug Resistance Protein 1 and Annexin A2 as Predictive Factors for Intravesical Recurrence of Bladder Cancer after the Initial Transurethral Resection and Immediate Single Intravesical Instillation of Adriamycin.
Sawazaki H; Ito K; Asano T; Kuroda K; Horiguchi A; Tsuda H; Asano T
Asian Pac J Cancer Prev; 2021 May; 22(5):1459-1466. PubMed ID: 34048174
[TBL] [Abstract][Full Text] [Related]
3. Increase in Circulating Tumor Cells in Invasive Bladder Cancer After Transurethral Resection of Bladder Tumor.
Haga N; Tsubouchi K; Maruta H; Koguchi T; Hoshi S; Ogawa S; Akaihata H; Hata J; Kojima Y
Anticancer Res; 2020 Aug; 40(8):4299-4307. PubMed ID: 32727757
[TBL] [Abstract][Full Text] [Related]
4. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.
Huang B; Wang H; Lin H; Yao Z; Zheng J; Fan W; Qiu S; Chen L; Chen J
J Cancer Res Clin Oncol; 2019 Feb; 145(2):487-494. PubMed ID: 30539282
[TBL] [Abstract][Full Text] [Related]
6. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
8. Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer.
Onishi T; Sekito S; Shibahara T; Yabana T
Urol Oncol; 2021 Feb; 39(2):132.e1-132.e6. PubMed ID: 32792215
[TBL] [Abstract][Full Text] [Related]
9. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
Gamal El-Deen HS
J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
[TBL] [Abstract][Full Text] [Related]
10. Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate: a comparative retrospective study.
Jaidane M; Bouicha T; Slama A; Hmida W; Hidoussi A; Ben Sorba N; Mosbah F
Urology; 2010 Jun; 75(6):1392-5. PubMed ID: 19781747
[TBL] [Abstract][Full Text] [Related]
11. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
[TBL] [Abstract][Full Text] [Related]
13. Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma.
Aboziada MA; Hamza HM; Abdlrahem AM
J Egypt Natl Canc Inst; 2009 Jun; 21(2):167-74. PubMed ID: 21057568
[TBL] [Abstract][Full Text] [Related]
14. The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
Elsawy AA; El-Assmy AM; Bazeed MA; Ali-El-Dein B
Urol Oncol; 2019 Mar; 37(3):179.e9-179.e18. PubMed ID: 30448030
[TBL] [Abstract][Full Text] [Related]
15. How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices.
Sountoulides P; Mutomba WF; Bouras E; Lim J; Bourdoumis A; Jain A
Urologia; 2020 Aug; 87(3):142-148. PubMed ID: 31959070
[TBL] [Abstract][Full Text] [Related]
16. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
[TBL] [Abstract][Full Text] [Related]
17. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
[TBL] [Abstract][Full Text] [Related]
18. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
Pieras E; Palou J; Salvador J; Rosales A; Marcuello E; Villavicencio H
Eur Urol; 2003 Aug; 44(2):222-5; discussoion 225. PubMed ID: 12875942
[TBL] [Abstract][Full Text] [Related]
19. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
20. The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.
Onishi T; Sekito S; Shibahara T; Uchida K; Sasaki T
Scand J Urol; 2018; 52(5-6):385-388. PubMed ID: 30628540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]